Neuronetics

Canaccord Genuity Acts as Financial Advisor to Neuronetics, Inc. on its Merger with Greenbrook TMS Inc.

Canaccord Genuity is pleased to announce that on December 10, 2024, Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”) announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook (the “Greenbrook Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Each Greenbrook Share outstanding immediately prior to the effective time of the Arrangement was exchanged for 0.01021 of a share of common stock of Neuronetics upon closing of the Arrangement.

Canaccord Genuity is serving as financial advisor to Neuronetics in connection with the transaction.

Neuronetics develops NeuroStar, a non-drug, non-invasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (”MDD”) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar is the leading Transcranial Magnetic Stimulation (“TMS”) treatment for MDD in adults with over 6.9 million treatments delivered.

Greenbrook is a leading provider of TMS and Spravato (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of MDD and other mental health disorders in the United States. Greenbrook has provided more than 1.7 million treatments to over 51,000 patients struggling with depression.

Canaccord Genuity is focused on the corporate finance needs associated with growth companies in the United States, Canada, Europe and Asia. We are structured to provide our clients with a full range of global investment banking services, including corporate finance, research, sales and trading. Our thematic research focusing on companies around the world provides our firm with unique access to growth investors. In the last two years, the firm advised on approximately 160 M&A transactions with aggregate disclosed value of $24 billion.